{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:59:03Z","timestamp":1787504343082,"version":"build-2736575974"},"reference-count":66,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T00:00:00Z","timestamp":1758412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Oradea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Large-scale bibliometric assessments of psoriasis pharmacotherapy research remain limited despite significant research output in this rapidly evolving field. This study aimed to map the evolution of systemic psoriasis therapy research over five decades and demonstrate how systematic analysis of research trajectories can illuminate the transformation of specialized medical fields into central components of precision medicine. Methods: A comprehensive bibliometric analysis was conducted using Web of Science Core Collection as the single data source, examining 19,284 publications spanning 1975\u20132025. The methodology employed AI-enhanced terminology normalization for standardizing pharmaceutical nomenclature, VOSviewer version 1.6.20 for network visualization, and Bibliometrix package for temporal trend analysis and thematic evolution mapping. International collaboration networks, thematic evolution across three distinct periods (1975\u20132000, 2001\u20132010, 2011\u20132025), and citation impact patterns were systematically analyzed. Results: Four distinct developmental phases were identified, with publications growing from 9 articles in 1975 to 1638 in 2024. The United States dominated research output with 5959 documents, while Canada achieved the highest citation efficiency at 62.65 citations per document. Global collaboration encompassed 70 countries organized into four regional clusters, with a 28-nation Asia\u2013Pacific\u2013Africa\u2013Middle East alliance representing the largest collaborative group. Citation impact peaked during 2001\u20132008, coinciding with revolutionary biological therapy introduction. Thematic evolution demonstrated systematic transformation from two foundational themes to nine specialized domains, ultimately consolidating into four core areas focused on targeted therapeutics and evidence-based methodologies. Keyword analysis demonstrated progression from basic immunological studies to sophisticated targeted interventions, evolving from tumor necrosis factor alpha inhibitors to contemporary interleukin-17\/interleukin-23 pathway targeting and Janus kinase inhibitors. Conclusions: Over five decades, psoriasis therapeutics research has shifted from a niche dermatological discipline to a central model for innovation in immune-mediated diseases. This evolution illustrates how bibliometric approaches can capture the dynamics of scientific transformation, offering strategic insights for guiding pharmaceutical innovation, shaping research priorities, and informing precision medicine strategies across inflammatory conditions.<\/jats:p>","DOI":"10.3390\/ph18091422","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T08:37:39Z","timestamp":1758530259000},"page":"1422","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tracing Five Decades of Psoriasis Pharmacotherapy: A Large-Scale Bibliometric Investigation with AI-Guided Terminology Normalization"],"prefix":"10.3390","volume":"18","author":[{"given":"Ada","family":"Radu","sequence":"first","affiliation":[{"name":"Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania"},{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7625-8177","authenticated-orcid":false,"given":"Andrei-Flavius","family":"Radu","sequence":"additional","affiliation":[{"name":"Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania"},{"name":"Department of Psycho-Neurosciences and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela S.","family":"Bungau","sequence":"additional","affiliation":[{"name":"Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania"},{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-6592","authenticated-orcid":false,"given":"Delia Mirela","family":"Tit","sequence":"additional","affiliation":[{"name":"Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania"},{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Andrei","family":"Negru","sequence":"additional","affiliation":[{"name":"Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania"},{"name":"Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e19325","DOI":"10.7717\/peerj.19325","article-title":"Advancements in Understanding and Treating Psoriasis: A Comprehensive Review of Pathophysiology, Diagnosis, and Therapeutic Approaches","volume":"13","author":"MR","year":"2025","journal-title":"PeerJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00403-024-02846-z","article-title":"Global Burden and Future Trends in Psoriasis Epidemiology: Insights from the Global Burden of Disease Study 2019 and Predictions to 2030","volume":"316","author":"Wang","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Gao, Y., Xu, T., Wang, Y., Hu, Y., Yin, S., Qin, Z., and Yu, H. (2025). Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17010056"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10787-024-01602-z","article-title":"Naturally Derived Bioactive Compounds as Precision Modulators of Immune and Inflammatory Mechanisms in Psoriatic Conditions","volume":"33","author":"Radu","year":"2024","journal-title":"Inflammopharmacology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bu, J., Ding, R., Zhou, L., Chen, X., and Shen, E. (2022). Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.880201"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.genhosppsych.2022.01.006","article-title":"Associations between Psoriasis and Mental Illness: An Update for Clinicians","volume":"75","author":"Hedemann","year":"2022","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.5114\/ada.2021.108445","article-title":"Treatments in Psoriasis: From Standard Pharmacotherapy to Nanotechnology Therapy","volume":"39","author":"Zhu","year":"2022","journal-title":"Post\u0119py Dermatol. I Alergol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Radu, A., Jurca, T., Radu, A.-F., Bodog, T.M., Bodog, R.F., and Endres, L. (2025). A Multimodal Approach to Managing Severe Psoriasis Vulgaris: A Case Report Leveraging Natural Therapies for Flare Control. Life, 15.","DOI":"10.3390\/life15081186"},{"key":"ref_10","first-page":"39","article-title":"Biologic Treatments of Psoriasis: An Update for the Clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"113388","DOI":"10.1016\/j.intimp.2024.113388","article-title":"Current Therapeutic Overview and Future Perspectives Regarding the Treatment of Psoriasis","volume":"143","author":"Ferrara","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"125385","DOI":"10.1016\/j.ijpharm.2025.125385","article-title":"A New Era of Psoriasis Treatment: Drug Repurposing through the Lens of Nanotechnology and Machine Learning","volume":"673","author":"Tarek","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/PTT.S328460","article-title":"Towards Personalized Medicine in Psoriasis: Current Progress","volume":"12","author":"Camela","year":"2022","journal-title":"Psoriasis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","article-title":"How to Conduct a Bibliometric Analysis: An Overview and Guidelines","volume":"133","author":"Donthu","year":"2021","journal-title":"J. Bus. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/bjd.15380","article-title":"Systematic Reviews and Meta-analyses on Psoriasis: Role of Funding Sources, Conflict of Interest and Bibliometric Indices as Predictors of Methodological Quality","volume":"176","author":"Ruano","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jclinepi.2018.05.015","article-title":"Relationships between Abstract Features and Methodological Quality Explained Variations of Social Media Activity Derived from Systematic Reviews about Psoriasis Interventions","volume":"101","author":"Ruano","year":"2018","journal-title":"J. Clin. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2346282","DOI":"10.1080\/09546634.2024.2346282","article-title":"Bibliometric Analysis and Description of Research Trends in the Treatment of Psoriasis with Biologic Agents in the Past Two Decades (2004\u20132023)","volume":"35","author":"Wang","year":"2024","journal-title":"J. Dermatolog. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e31054","DOI":"10.1016\/j.heliyon.2024.e31054","article-title":"Research Hotspots and Trends in Biological Agents for Psoriasis: Visualization and Bibliometric Analysis","volume":"10","author":"Long","year":"2024","journal-title":"Heliyon"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e29794","DOI":"10.1016\/j.heliyon.2024.e29794","article-title":"Development and Trends in Metabolomics Studies in Psoriasis: A Bibliometric Analysis of Related Research from 2011 to 2024","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000519191","article-title":"Bibliometric Trends in Nail Psoriasis Research Publications","volume":"8","author":"Gregoriou","year":"2022","journal-title":"Ski. Appendage Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e35446","DOI":"10.1016\/j.heliyon.2024.e35446","article-title":"Research Trends and Hotspots in Biologics for Plaque Psoriasis: A Bibliometric Study from 2004 to 2023","volume":"10","author":"Huang","year":"2024","journal-title":"Heliyon"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e23542","DOI":"10.1016\/j.heliyon.2023.e23542","article-title":"Bibliometric Analysis and Description of Research Trends on T Cells in Psoriasis over the Past Two Decades (2003-2022)","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1111\/ajd.13407","article-title":"Psoriasis: A Bibliometric Analysis in the Arab World (2004-2019)","volume":"62","author":"Daou","year":"2021","journal-title":"Australas J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4103\/2320-0057.128997","article-title":"Indian Psoriasis Research: An Impact Assessment through Bibliometric Studies","volume":"2","author":"Ram","year":"2013","journal-title":"J. Scientometr. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3946320241290341","DOI":"10.1177\/03946320241290341","article-title":"Mapping the Psoriasis Research Landscape: A Comprehensive Bibliometric Analysis from 2012-2023","volume":"38","author":"Garg","year":"2024","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Tiuc\u0103, O.M., Morariu, S.H., Mariean, C.R., Tiuc\u0103, R.A., Nicolescu, A.C., and Cotoi, O.S. (2023). Research Hotspots in Psoriasis: A Bibliometric Study of the Top 100 Most Cited Articles. Healthcare, 11.","DOI":"10.3390\/healthcare11131849"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/ajcn\/54.3.438","article-title":"Omega-3 Fatty Acids in Health and Disease and in Growth and Development","volume":"54","author":"Simopoulos","year":"1991","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/07315724.2002.10719248","article-title":"Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases","volume":"21","author":"Simopoulos","year":"2002","journal-title":"J. Am. Coll. Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-Mediated Inflammatory Disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor Necrosis Factor Antagonist Mechanisms of Action: A Comprehensive Review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis\u2014Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and Safety of Ustekinumab, a Human Interleukin-12\/23 Monoclonal Antibody, in Patients with Psoriasis: 76-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of Myocardial Infarction in Patients with Psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of Cardiovascular Risk Factors in Patients with Psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as Monotherapy in Patients with Psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab Induction and Maintenance Therapy for Moderate-to-Severe Psoriasis: A Phase III, Multicentre, Double-Blind Trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab Therapy for Moderate to Severe Psoriasis: A Randomized, Controlled Phase III Trial","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 1. Overview of Psoriasis and Guidelines of Care for the Treatment of Psoriasis with Biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-Wide Scan Reveals Association of Psoriasis with IL-23 and NF-KappaB Pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and Safety of Guselkumab, an Anti-Interleukin-23 Monoclonal Antibody, Compared with Adalimumab for the Continuous Treatment of Patients with Moderate to Severe Psoriasis: Results from the Phase III, Double-Blinded, Placebo- and Active Comparator-","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of Ixekizumab with Etanercept or Placebo in Moderate-to-Severe Psoriasis (UNCOVER-2 and UNCOVER-3): Results from Two Phase 3 Randomised Trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Belli, R., Dattolo, A., Sampogna, F., Gubinelli, E., Lulli, D., Moretta, G., Scala, E., Sanna, L., Megna, M., and Cannizzaro, M.V. (2025). Leptin: A Gender and Obesity-Related Marker Predictive of Metabolic Comorbidities and Therapeutic Response to Anti-IL-23 Biologic Drugs in Psoriatic Patients. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1607312"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1007\/s12325-025-03240-5","article-title":"Multiple Switches Between Adalimumab-Fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability","volume":"42","author":"Deodhar","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaad.2025.03.018","article-title":"Efficacy and Safety of SYSA1902 versus Reference Ustekinumab in Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Phase III Study","volume":"93","author":"Xia","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jaad.2025.01.089","article-title":"Effect of Spesolimab on Sustained Disease Control in Patients with Generalized Pustular Psoriasis: Post Hoc Analysis of the EFFISAYIL 2 Study","volume":"92","author":"Gordon","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/1346-8138.17744","article-title":"Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In-Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO-4 Trial","volume":"52","author":"Okubo","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13287-025-04415-1","article-title":"Novel Sponge Formulation of Mesenchymal Stem Cell Secretome and Hyaluronic Acid: A Safe and Effective Topical Therapy for Psoriasis Vulgaris","volume":"16","author":"Elgueta","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The Effects of Tumour Necrosis Factor Inhibitors, Methotrexate, Non-Steroidal Anti-Inflammatory Drugs and Corticosteroids on Cardiovascular Events in Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_53","unstructured":"Web of Science Core Collection (2025, July 25). Research with Confidence: Explore the Web of Science Core Collection Database. Available online: https:\/\/clarivate.com\/academia-government\/scientific-and-academic-research\/research-discovery-and-referencing\/web-of-science\/web-of-science-core-collection\/."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Pranckut\u0117, R. (2021). Web of Science (WoS) and Scopus: The Titans of Bibliographic Information in Today\u2019s Academic World. Publications, 9.","DOI":"10.3390\/publications9010012"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software Survey: VOSviewer, a Computer Program for Bibliometric Mapping","volume":"84","author":"Waltman","year":"2010","journal-title":"Scientometrics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","article-title":"Bibliometrix: An R-Tool for Comprehensive Science Mapping Analysis","volume":"11","author":"Aria","year":"2017","journal-title":"J. Informetr."},{"key":"ref_57","unstructured":"(2025, July 15). RStudio Team. Available online: https:\/\/posit.co\/."},{"key":"ref_58","unstructured":"(2025, July 15). Python 3.12.3. Available online: https:\/\/www.python.org\/downloads\/release\/python-3123\/."},{"key":"ref_59","unstructured":"Mckinney, W. (July, January 28). Data Structures for Statistical Computing in Python. Proceedings of the 9th Python in Science Conference, Austin, TX, USA."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: A 2D Graphics Environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Comput. Sci. Eng."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.21105\/joss.03021","article-title":"Seaborn: Statistical Data Visualization","volume":"6","author":"Waskom","year":"2021","journal-title":"J. Open Source Softw."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-020-2649-2","article-title":"Array Programming with NumPy","volume":"585","author":"Harris","year":"2020","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Reimers, N., and Gurevych, I. (2019, January 3\u20137). Sentence-BERT: Sentence Embeddings Using Siamese BERT-Networks. Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing and the 9th International Joint Conference on Natural Language Processing (EMNLP-IJCNLP), Hong Kong, China.","DOI":"10.18653\/v1\/D19-1410"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/bioinformatics\/btz682","article-title":"BioBERT: A Pre-Trained Biomedical Language Representation Model for Biomedical Text Mining","volume":"36","author":"Lee","year":"2020","journal-title":"Bioinformatics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cageo.2011.12.017","article-title":"A Density-Based Spatial Clustering Algorithm Considering Both Spatial Proximity and Attribute Similarity","volume":"46","author":"Liu","year":"2012","journal-title":"Comput. Geosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"48","DOI":"10.55151\/ijeedu.v7i1.188","article-title":"A Comparative Analysis of Python Text Matching Libraries: A Multilingual Evaluation of Capabilities, Performance and Resource Utilization","volume":"7","author":"Elmobark","year":"2025","journal-title":"Int. J. Environ. Eng. Educ."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/9\/1422\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:43Z","timestamp":1760035603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/9\/1422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,21]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ph18091422"],"URL":"https:\/\/doi.org\/10.3390\/ph18091422","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,21]]}}}